HC Wainwright Has Pessimistic Outlook of Myomo Q3 Earnings

Myomo, Inc. (NYSEAMERICAN:MYO) – Research analysts at HC Wainwright lowered their Q3 2025 earnings per share estimates for shares of Myomo in a note issued to investors on Tuesday, August 12th. HC Wainwright analyst S. Lee now expects that the company will earn ($0.10) per share for the quarter, down from their previous estimate of ($0.03). HC Wainwright currently has a “Buy” rating and a $5.00 price objective on the stock. The consensus estimate for Myomo’s current full-year earnings is ($0.18) per share. HC Wainwright also issued estimates for Myomo’s Q4 2025 earnings at ($0.02) EPS, FY2025 earnings at ($0.36) EPS, Q1 2026 earnings at ($0.09) EPS, Q2 2026 earnings at ($0.07) EPS, Q3 2026 earnings at ($0.06) EPS, Q4 2026 earnings at $0.02 EPS, FY2026 earnings at ($0.19) EPS, FY2027 earnings at ($0.02) EPS, FY2028 earnings at $0.19 EPS and FY2029 earnings at $0.35 EPS.

MYO has been the subject of a number of other research reports. Alliance Global Partners reissued a “buy” rating on shares of Myomo in a research report on Thursday, June 26th. Craig Hallum set a $8.00 price target on Myomo and gave the stock a “buy” rating in a research note on Monday, June 23rd. Finally, Ascendiant Capital Markets increased their price objective on shares of Myomo from $11.00 to $11.50 and gave the company a “buy” rating in a research report on Thursday, June 5th.

Myomo Price Performance

Shares of MYO stock opened at $0.98 on Thursday. The company’s 50-day moving average is $2.12. Myomo has a 1-year low of $0.92 and a 1-year high of $7.17. The company has a debt-to-equity ratio of 0.08, a quick ratio of 2.37 and a current ratio of 2.39. The company has a market capitalization of $36.86 million, a P/E ratio of -4.24 and a beta of 1.40.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the stock. Soleus Capital Management L.P. acquired a new stake in Myomo during the 4th quarter worth $5,796,000. Rosalind Advisors Inc. lifted its stake in shares of Myomo by 33.0% in the second quarter. Rosalind Advisors Inc. now owns 3,595,788 shares of the company’s stock worth $7,767,000 after buying an additional 892,127 shares in the last quarter. AIGH Capital Management LLC boosted its position in Myomo by 22.3% during the second quarter. AIGH Capital Management LLC now owns 3,555,742 shares of the company’s stock worth $7,680,000 after acquiring an additional 649,053 shares during the last quarter. Geode Capital Management LLC grew its stake in Myomo by 160.8% during the 2nd quarter. Geode Capital Management LLC now owns 669,281 shares of the company’s stock valued at $1,446,000 after acquiring an additional 412,631 shares in the last quarter. Finally, Manatuck Hill Partners LLC acquired a new stake in Myomo in the 4th quarter valued at about $1,582,000. Institutional investors and hedge funds own 44.99% of the company’s stock.

About Myomo

Myomo, Inc, a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States, China, Germany, and internationally. The company offers MyoPro, a myoelectric-controlled upper limb brace or orthosis product used for supporting a patient’s weak or paralyzed arm to enable and improve functional activities of daily living.